ABSTRACT: The functions of the paralogous transcriptional coactivators Yes-associated protein (YAP) and transcriptional coactivator with PDZ-binding motif (TAZ) in bone are controversial. Each has been observed to promote or inhibit osteogenesis in vitro, with reports of both equivalent and divergent functions. Their combinatorial roles in bone physiology are unknown. We report that combinatorial YAP/TAZ deletion from skeletal lineage cells, using Osterix-Cre, caused an osteogenesis imperfecta-like phenotype with severity dependent on allele dose and greater phenotypic expressivity with homozygous TAZ vs. YAP ablation. YAP/TAZ deletion decreased bone accrual and reduced intrinsic bone material properties through impaired collagen content and organization. These structural and material defects produced spontaneous fractures, particularly in mice with homozygous TAZ deletion and caused neonatal lethality in dual homozygous knockouts. At the cellular level in vivo, YAP/TAZ ablation reduced osteoblast activity and increased osteoclast activity, in an allele dose-dependent manner, impairing bone accrual and remodeling. Transcriptionally, YAP/TAZ deletion and small-molecule inhibition of YAP/TAZ interaction with the transcriptional coeffector TEAD reduced osteogenic and collagen-related gene expression, both in vivo and in vitro. These data demonstrate that YAP and TAZ combinatorially promote bone development through regulation of osteoblast activity, matrix quality, and osteoclastic
Bone is a living hierarchical composite, with form and function dependent not only on tissue structure but also on matrix composition and organization. Each of these components is controlled during development by skeletal cell lineage progression and by dynamic regulation of bone deposition and remodeling. Various genetic, hormonal, or environmental abnormalities can impair these processes, leading to debilitating diseases including osteoporosis and osteogenesis imperfecta (OI). However, the molecular mechanisms that govern cell fate and matrix production in bone remain poorly understood, limiting therapeutic intervention. Several transcriptional programs have been described as essential regulators of bone development, but current understanding is insufficient to fully explain the heterogeneity found in congenital and acquired bone diseases (1) (2) (3) . In this study, we sought to define the functions of the paralogous transcriptional coactivators yes-associated protein (YAP) and transcriptional coactivator with PDZ-binding motif (TAZ) in bone development.
YAP/TAZ functional diversity
YAP and TAZ (also known as WWTR1) display either equivalent or divergent functions, depending on cell type and context (4) . YAP and TAZ possess transcription activation domains, but they lack DNA-binding domains and require interaction with cofactors for transcriptional activity (5) . Their most potent and well-studied interactions are with the transcriptional enhancer activator domain (TEAD) family proteins, which themselves lack activation domains, providing specificity for YAP/TAZ-TEAD signaling (6) . However, other coeffectors are also known, including runt-related transcription factor (Runx)-2 (7), b-catenin (8) (9) (10) , and Smad2/3 (11, 12) , each of which contributes to bone development and osteoprogenitor lineage progression (13) (14) (15) (16) (17) . Thus, independent pathways that regulate coincident activation of these various binding partners could provide additional layers of contextual specificity in bone. Further, as paralogues, the YAP and TAZ proteins also possess structural differences (reviewed in Ref. 18 ) that enable distinct protein interactions to confer unique physiologic functions of YAP vs. TAZ. Notably, global YAP deletion in mice is embryonic lethal [embryonic day (E)8.5] because of impaired-yolk sac vasculogenesis (19) , whereas the global TAZ knockout lives to maturity with modest skeletal defects and polycystic kidney disease (20) , demonstrating conclusive genespecific functions. However, in other contexts, they exhibit clear functional homology, with either protein capable of compensation for the other (21, 22) .
YAP and TAZ function in bone: conflicting evidence
Roles for YAP and TAZ in osteogenesis were first described in 2004 and 2005, respectively (23, 24) . YAP was reported to suppress osteoblastic differentiation through sequestration and transcriptional repression of Runx2 (23) , whereas TAZ was identified as a Runx2 coactivator and an inhibitor of the adipogenic nuclear receptor, peroxisome proliferator-activated receptor-g (24, 25) . A subsequent study found that overexpression of a constitutively active YAP mutant in marrow stromal cells (MSCs) promoted osteogenic differentiation, even under conditions more favorable for adipogenesis (26) . In contrast, another report found that YAP overexpression inhibits osteogenesis in MSCs by suppressing activation of wingless-type (WNT) target genes (27) . The role of TAZ in osteogenic differentiation in vitro is similarly complicated, with reports demonstrating both inhibition (28) and induction (29) of osteogenic differentiation by modulating the canonical WNT pathway. In vivo, osteoblast-specific overexpression of TAZ promotes bone formation with higher expression levels of Runx2 expression (30) , whereas YAP overexpression in chondrocytes impairs cartilage template formation during endochondral bone development (31) . Together, these observations suggest the importance of YAP and TAZ in bone, but the conflicting evidence remains unresolved and their combinatorial roles in bone physiology remain unknown. To address these questions, we implemented a combinatorial deletion approach in vivo to evaluate the influence of allele dose-dependent YAP/TAZ deletion on bone development. 
MATERIALS AND METHODS

Animals
Skeletal preparations
Skeletal preparations were stained with Alcian blue (A3157; Millipore-Sigma) and Alizarin red (A5533; both from MilliporeSigma, Billerica, MA, USA) (33) .
Histology and histomorphometric analysis
Bone samples were fixed and decalcified according to standard procedures. Paraffin-embedded sections (5 mm thickness) were processed for either immunohistochemistry or histology. Primary antibodies were compared to negative control sections. 
Micro-computed tomography
Harvested femora from 8-wk-old mice were stored at 220°C until evaluation. Frozen specimens were thawed and imaged with a vivaCT 80 scanner (Scanco Medical, Zurich, Switzerland) to determine trabecular and cortical femoral bone architecture before mechanical testing to failure in 3-point bending. The mid diaphysis and distal femur were imaged with an X-ray intensity of 114 mA, energy of 70 kVp, integration time of 300 ms, and resolution of 10 mm. Mid-diaphyseal and distal femoral 2-dimensional tomograms were manually contoured, stacked, and binarized by applying a Gaussian filter (s = 1, support = 1) at a threshold of 250 mg HA/cm 3 .
Mechanical testing
Mechanical analysis of the femurs was carried out by 3-point bend testing. The femurs were loaded with the condyles facing down onto the bending fixtures, with a lower span length of 4.4 mm. The upper fixture was aligned with the mid diaphysis. The femora were loaded to failure at a rate of 0.5 mm/s by the ElectroForce 3220 Series testing system (TA Instruments, New Castle, DE, USA). ) containing 30 ml osteogenic induction medium, which included 2 mg/ml b-glycerophosphate, 50 mM dexamethasone, and 3.75 mg/ml ascorbic acid to the previously described medium without doxycycline or FGF-2. The osteogenic medium was changed every other day before RNA isolation.
Imaging
UMR-106 cell culture
Osteoblast-like UMR-106 cells (UMRs) were cultured in DMEM containing 4 mM L-glutamine, 4500 mg/L glucose, 1 mM sodium pyruvate, 1500 mg/L sodium bicarbonate, and 10% fetal bovine serum according to American Type Culture Collection ; ATCC, Manassas, VA, USA) recommendations. UMRs at 50 % confluence in 96-well plates were transfected in antibiotic-free medium for 4 h with 4 previously described luciferase reporter constructs: 1) Runx2-responsive 6xOSE2, 2) 657 bp osteocalcin (OCN) promoter (35), 3) TEAD-responsive 8XGTIIC (Addgene, Cambridge, MA, USA), and a control Renilla plasmid, kindly provided by Munir Tanas (University of Iowa, Iowa City, IA). Forty-eight hours after transfection, UMRs were treated with either DMSO or 0.5 or 1 mM verteporfin (VP) in serum-free conditions for 1 h. All VP experiments were performed in the dark to prevent photoactivation. Cells were then lysed immediately using the Dual-Luciferase Reporter Assay System according to the manufacturer's instructions (Promega, Madison, WI, USA). Luciferase activity was measured on a Victor 3 (PerkinElmer, Waltham, MA, USA) plate reader and normalized to baseline Renilla activity (36) . Separately cultured UMR-106 cells were seeded (4 3 10 3 cells/cm 2 ) onto 6-well plates and simultaneously treated with DMSO or 0.5 or 1 mM VP and cultured under serum-free conditions for 1 h before RNA isolation.
VP delivery in vivo
Six littermate control (4 male and 2 female) mice (YAP WT ;TAZ WT ) were aged 16 wk. Three mice each (2 males and 1 female each) were assigned to VP or vehicle control (DMSO) groups. In brief, DMSO-solubilized VP was diluted in 0.9% saline and injected intraperitoneally every other for day for 2 wk. Control animals received corresponding injections of DMSO in 0.9% saline. Livers and femurs from both VP-and DMSO-treated mice were harvested on the day of the last injection for RNA isolation.
RNA isolation and quantitative PCR
Total bone and liver samples were snap frozen in liquid nitrogen-cooled isopentane for 1 min before storage at 280°C until processing. Tissue was then homogenized in a mortar and pestle, and RNA from the sample was collected with TRIzol Reagent (Thermo Fisher Scientific) followed by centrifugation in chloroform. RNA from both bone tissue samples and in vitro experiments were purified with the RNA Easy Kit (Qiagen, Germantown, MD, USA) and quantified by spectrophotometry with a NanoDrop 2000 (Thermo Fisher Scientific). RT-PCR was performed on 0.5 mg/ml concentration of RNA with the TaqMan Reverse Transcription Kit (Thermo Fisher Scientific). Quantitative PCR (qPCR) assessed RNA amount using a CFX Connect (Bio-Rad, Hercules, CA, USA) relative to the internal control of glyceraldehyde 3-phosphate dehydrogenase (GAPDH). Data are presented using the 2 2DDCt method. Specific mouse and rat primer sequences are listed ( Table 2) .
Statistics and regression
All statistics and regression analyses were performed in Prism (GraphPad. San Diego, CA, USA) or using R (v2.13.1). Comparisons between 2 groups were made using the independent t test, whereas comparisons between 3 or more groups were made with a 1-way ANOVA with post hoc Bonferroni's multiple comparisons test, if the data were normally distributed according to D'Agostino-Pearson omnibus normality test and homoscedastic according to Bartlett's test. When parametric test assumptions were not met, data were log transformed, and residuals were evaluated. If necessary, the nonparametric Kruskal-Wallis test with post hoc Dunn's multiple comparisons was used. Significance was set at P , 0.05 (adjusted for multiple comparisons). Data are represented as individual samples with means 6 SEM. Multivariate analysis was performed according to a previously described procedure, with some modifications (37) . In brief, we used an exhaustive best-subsets algorithm to determine the best predictors of maximum load and stiffness from a subset of morphologic parameters measured, which included a moment of inertia (I ) or section modulus (I/c), tissue mineral density (TMD), and second harmonic generated (SHG) intensity based on Akaike's information criterion (AIC) (38) . The lowest AIC selects the best model while giving preference to less complex models (those with fewer explanatory parameters). Finally, the overall best model for each predicted mechanical property was compared to the prediction from only the moment of inertia (I/c or I for maximum load and stiffness, respectively) using type II general linear regression. Sample sizes were selected a priori by power analysis based on effect sizes and population SD taken from published data on YAP fl/ fl ;TAZ fl/fl mice in other tissues (22) , assuming a power of 80% and a = 0.05.
RESULTS
YAP/TAZ expression and deletion in bone
To determine YAP/TAZ expression profiles in bone, we immunostained YAP and TAZ in the growth plate and cancellous and cortical bone of 8-wk-old C57Bl6/J mouse femora. YAP and TAZ immunolocalized in hypertrophic chondrocytes, osteoblasts, and osteocytes with minimal detectable expression in quiescent or proliferating chondrocytes (Supplemental Fig. S1A ). Based on these expression patterns, we chose to evaluate the physiologic roles of YAP and TAZ by combinatorial conditional ablation (22) in cells of the skeletal lineage using Osterix-Cre (32). We selected a breeding strategy that yielded littermates with variable YAP/ TAZ allele dose. To assess Cre-mediated recombination Mouse gene
and deletion of YAP and TAZ, we measured mRNA expression in femoral bone preparations by qPCR (Supplemental Fig. S1B ) and verified the absence of protein expression by bone cells in conditional knockout (cKO) mice by immunohistochemistry (Supplemental Fig. S1C ). YAP/TAZ expression in skeletal cells was reduced by 50-80% by Osterix-Cre-mediated excision (Supplemental Fig. S1B , C).
Neonatal lethality and hypermineralization
All Osterix-cKOs and littermate controls were born at expected Mendelian ratios, but dual homozygous conditional deletion (YAP cKO ;TAZ cKO ) caused neonatal asphyxiation secondary to ribcage malformation and fracture (Fig. 1A-C) , resulting in 75% mortality at postnatal d (P)0 and 99% by P7 (Fig. 1B) 1A , C-E). Spontaneous extremity fractures were not present in other genotypes at P0 (Fig. 1A) . Littermate neonates displayed reduced whole-skeleton bone volume ( Fig. 1F ; P , 0.05, ANOVA) and significantly elevated bone TMD ( Fig. 1G ; P , 0.01, ANOVA) with dual homozygous conditional YAP/TAZ deletion. Osterixconditional YAP/TAZ deletion also significantly reduced birth weight and intact femoral length in an allele dose-dependent manner (Supplemental Fig. S2 ). Males Fig. 2A,  B) , with significantly increased femoral fracture incidence in the YAP cHET ;TAZ cKO mice (Fig. 2C) . Fractures healed by endochondral repair in all groups, though YAP cHET ;TAZ cKO and YAP cKO ;TAZ cKO calluses exhibited empty lacunae in the hypertrophic transition zone, suggesting increased hypertrophic chondrocyte death or insufficient progenitor cell recruitment (Fig. 2C c.f. Fig. 2D ). Consistently, staining of Osterix + cells was qualitatively reduced in the transition zone of the YAP cKO ;TAZ cKO growth plate, but differences in the thickness of resting (RZ), proliferating (PZ), and hypertrophic (HZ) zones of the growth plate did not reach significance at either P10 (Fig. 2E-G) or P56 (Supplemental Fig. S3A, B) .
Reduced cortical and cancellous microarchitectural properties YAP/TAZ deletion from osteoblast precursor cells and their progeny altered cancellous (Fig. 3A, B) and cortical bone (Fig. 3C, D) in adolescent mice (P56) according to allele dose. Distal femur metaphyseal cancellous bone exhibited reduced trabecular bone volume fraction (bone volume/total volume), thickness, and number, and increased spacing and structural model index (indicative of more rod-like trabeculae) (Fig. 3B and Supplemental Fig.  S4A-C) . The cumulative distribution of trabecular thicknesses shifted in an allele dose-dependent manner, toward reduced numbers of both small and large trabeculae (Supplemental Fig. S4B ). Volumetric bone mineral density (vBMD) was not altered, suggesting an increase in local TMD proportional to the decrease in trabecular bond volume (Fig. 3B) . The mid diaphyseal femoral cortical bone (Fig. 3C, D and Supplemental Fig. S4D, E) similarly exhibited reduced thickness, area (B.Ar), and moment of inertia (I) in cKO mice, attributable to reduced periosteal and endocortical bone accumulation, as indicated by significant reductions in endocortical perimeter, periosteal perimeter, and B.Ar. Consistent with the observations of vBMD in the cancellous compartment, cortical TMD was significantly increased in an allele dose-dependent manner; however, unlike the cancellous bone, the increase in TMD of the cortical bone was insufficient to normalize bone mass lost by reduced bone volume.
Reduced intrinsic bone mechanical properties and matrix collagen content and microstructure
In general, extrinsic bone properties (e.g., failure load, bending stiffness) depend on both the intrinsic mechanical properties of the bone matrix and the bone amount and cross-sectional distribution. To determine whether Osterix-conditional YAP/TAZ deletion impaired bone matrix quality, we performed a 3-point bending test to failure on each femur previously analyzed by micro-CT (Fig. 4A, B) . YAP/TAZ deletion reduced stiffness, maximum force at failure, work to maximum load, and work to failure (Fig. 4C-F) . Because the assumptions of EulerBernoulli beam theory were decidedly not met in the 3-point bending test of mouse long bones (39, 40), we performed an ANCOVA with linear regression (Fig. 4G,  H) , to decouple the contributions of bone quantity and distribution from the mechanical behavior (41) . If the variability in extrinsic mechanical properties is best predicted by individual regression lines for each genotype, this would indicate differences in intrinsic matrix mechanical properties between genotypes; however, a best fit by a single regression line for all groups would indicate that differences in extrinsic behavior are sufficiently described merely by changes in bone geometry. We found that individual regression lines for each genotype best predicted maximum load at failure, indicating significant differences in intrinsic failure properties (Fig. 4G) . In contrast, a single regression line best fit the stiffness data ( Fig. 4H) , indicating that the differences in stiffness can be attributed to changes in moment of inertia rather than intrinsic matrix elastic properties. As a composite material, quasi-static bone mechanical behavior is determined predominantly by its 2 primary matrix components: mineral and collagen. We noted above that femora from mice with Osterixconditional YAP/TAZ deletion exhibited moderate hypermineralization (Fig. 3D) . Next, to characterize the bone matrix collagen in these same samples, we performed polarized light microscopy of Picrosirius red-stained sections (Fig. 5A) and SHIM (Fig. 5B) (42) . Both approaches revealed that YAP/TAZ deletion significantly reduced local collagen content and organization (Fig. 5C) . Therefore, to determine the contributions of geometry, mineralization, and collagen content and microstructure to bone mechanical behavior, we performed a best-subsets correlation analysis to identify significant predictors based on AIC (37, 38) . For both elastic (Fig. 5D) and failure (Fig. 5E) properties, bone TMD was not a significant predictor; however, moment of inertia and SHG intensity significantly improved the model's capability to explain variation (R adj 2 = 73 and 88% for stiffness and maximum load, respectively) and reduced AIC (Supplemental Fig. S5 ). Addition of TMD to the models did not improve predictive power or AIC.
Static histomorphometric analysis of Osterixconditional YAP/TAZ-deficient P56 femora revealed an allele dose-dependent decrease in the number of periosteal osteoblasts per bone surface (Ob.N/BS), but a dose-dependent increase in osteoclast surface vs. bone surface (Oc.S/BS) in the metaphyseal secondary spongiosa (Fig. 6A, B, D, E) . Cortical osteocyte density (Ot.N/B.Ar) was not significantly altered (Fig. 6A, F) . Dynamic histomorphometric analysis of Osterixconditional YAP/TAZ deficient P28 femora revealed no significant differences in mineralizing surface percentage (MS/BS), whereas the mineral apposition rate (MAR) was significantly reduced, according to allele dose (Fig. 6C, G, H) . Differences in bone formation rate (BFR/BS) did not reach statistical significance (Fig. 6C,  I ). YAP/TAZ deletion similarly altered fluorescent labeling of epiphyseal and metaphyseal cancellous bone compartments (Supplemental Fig. S6 ).
YAP/TAZ deletion and acute YAP/TAZ-TEAD inhibition reduced osteogenic and collagen-related gene expression
To identify potential YAP/TAZ transcriptional targets, we evaluated expression of candidate genes known to regulate osteogenesis or whose mutations cause OI in MSCs isolated from WT and Osterix-conditional YAP cKO ;TAZ cKO mice. For all tested genes, mRNA expression levels were equivalent before osteogenic induction, verifying Osterix-dependence of gene recombination (Supplemental Fig. S7 ). However, after 7 d in osteogenic medium, Osterix-conditional Cre-mediated recombination significantly reduced TAZ mRNA expression, whereas the reduction in YAP expression did not reach statistical significance (Fig. 7A, B) . However, mRNA expression of canonical YAP/TAZ target genes, cysteine-rich angiogenic inducer 61 and connective tissue growth factor (Ctgf), was significantly reduced (Supplemental Fig. S8A, B) . Of the collagen-related genes, mRNA expression of Col1a1and serine proteinase inhibitor clade H (SerpinH)-1, but not Col1a2, Col2, or Col10 was significantly reduced in YAP/TAZ cKO cells (Fig. 7C-E and Supplemental Fig. S8C, D) . were significantly reduced, but expression of Runx2 and Osterix were not altered (Fig. 7F-J) .
We next sought to determine whether this gene regulation was dependent on YAP/TAZ-TEAD in osteoblastlike cells by using a small molecule inhibitor, VP, which blocks YAP/TAZ interaction with TEAD (43) . We found that VP treatment of osteoblast-like UMR-106 cells reduced expression of the known YAP/TAZ-TEAD target gene CTGF, concomitant with reduced YAP/TAZ-TEAD-sensitive synthetic promoter activity (8xGTIIC-lux) (Fig. 7K) . mRNA expression of OI-related genes Col1a1 and Col1a2 was reduced by YAP/TAZ-TEAD inhibition, whereas differences in SerpinH1 expression did not reach statistical significance (Fig. 7L) . VP treatment did not alter Runx2 transcriptional activity (OSE2-lux) or Runx2 and Osterix expression levels, but reduced Ocn promoter activity (Ocn-657 bp-lux) concomitant with reduced expression of Bsp and Alp mRNA (Fig. 7M, N) .
To determine whether YAP and TAZ regulate expression of these genes in vivo, we performed real-time qPCR amplification of mRNA transcripts isolated from femoral cortical bone preparations. Osterix-conditional YAP/TAZ deletion significantly reduced Col1a1 and SerpinH1 expression in a manner dependent on allele dose (Fig. 8A, B) . No differences in Col1a2 (Supplemental Fig. S9A) , Col2a1, or Col10 (Supplemental Fig. S9B , C) expression were observed. Similarly, gene expression of osteogenic transcripts, Runx2, Osx, Ocn, Alp, and Bsp did not exhibit any significant differences in expression levels in vivo (Supplemental Fig. S9D-G) . Next, we evaluated whether YAP/TAZ-TEAD regulate the identified collagen-related candidate genes in vivo by acute YAP/TAZ inhibition in WT mice by VP injection. VP delivery (100 mg/kg i.p. injection every other day for 2 wk) significantly reduced expression of CTGF and SerpinH1 in liver tissue in vivo, but reductions in Col1a1 expression in liver and CTGF, Col1a1, and SerpinH1 in bone did not reach statistical significance (Fig. 8C, D) . 
DISCUSSION
Reports on the roles of YAP and TAZ in bone are contradictory (23) (24) (25) (26) (27) (28) (29) (30) (44) (45) (46) . To resolve these apparent conflicts in a physiologic context, we performed combinatorial conditional YAP/TAZ deletion in mice to dissect the roles of YAP and TAZ in the cells of the osteoblast lineage, from the precursors to terminal osteocytes, using Osterix-Cre. Our data reveal that YAP and TAZ have combinatorial roles in promoting osteogenesis by regulating bone formation, remodeling, and matrix mechanical properties.
YAP/TAZ deletion from skeletal cells phenocopies OI
Bone cell-conditional YAP/TAZ deletion caused skeletal defects similar to OI, with severity dependent on allele dose. OI is a highly heterogeneous group of inherited genetic diseases characterized by bone fragility and deformity, whose severity varies from mildly increased fracture risk to perinatal lethality (47) . YAP/ TAZ cKO mice mimicked clinical OI (48) and several established OI mouse models (49-51) with reduced bone volume in both cancellous and cortical compartments. For example, the human Col1a1 minigene mouse (49, 50), which expresses a human transgene containing a clinically observed mutation in proa 1 (I) collagen, dosedependently reproduces the phenotypes seen in Osterixconditional YAP/TAZ knockouts, including neonatal lethality at high transgene dose and spontaneous femoral fractures and reduced failure, but not elastic, bone material properties at moderate dose. Similarly, the naturally occurring oim mouse, caused by a frameshift mutation in proa 2 (I) collagen, also features reduced bone mechanical properties and increased fracture incidence with elevated mineral density (51, 52), a product of increased mean tissue age. In addition, multivariate regression analyses revealed intrinsic matrix mechanical property deficiencies in YAP/TAZ cKO mice similar to the oim mouse, also attributable to defects in local collagen content and organization (52, 53) . Similarly, conditioned medium from osteoprogenitor cells isolated from oim mice increased osteoclast formation in vitro (54), consistent with our observation of increased osteoclast activity in Osterix-conditional YAP/TAZ knockout bone. This finding suggests altered osteoclast recruitment and activation as a result of defective skeletal cell communication. Because global YAP deletion is embryonic lethal in animal models, loss-offunction mutations in YAP/TAZ are unlikely to be a cause of human OI; however, many pathways including TGF-b-Smad2/3 (11, 12) and WNT-b-catenin (9, 10) converge on YAP/TAZ, which could place this signaling axis upstream of the human disease. Further research is needed to evaluate whether YAP/TAZ signaling is causally linked to clinical OI. The elucidation of this pathway in bone may contribute new insights into the heterogeneity and etiology of the disease.
YAP/TAZ compensatory function
Mice possessing a single copy of either gene in Osterixexpressing cells rescued the lethality found in dual homozygous knockouts, indicating mutual compensatory function. However, mice with homozygous deletion of TAZ (i.e., YAP cHET ;TAZ cKO ) exhibited consistently cHET for all outcome measures, including bone formation, osteoclast activity, and bone quality. This result suggests that either TAZ is the more potent of the 2 paralogues in bone or that the 2 floxed loci exhibited differential efficiency of Cre-mediated excision. This latter possibility is supported by the greater reduction in TAZ expression observed in differentiating MSCs isolated from YAP fl/fl ;TAZ fl/fl ;Osx-Cre mice; however, in vivo, mRNA and protein levels of YAP and TAZ were similarly reduced. Thus, further study is necessary to elucidate potentially distinct coeffectors or transcriptional efficiency for YAP vs. TAZ in bone. A recent report demonstrated a unique binding mode of TAZ to TEAD4 based on crystal structure, suggesting a potential difference in regulatory function of TAZ vs. YAP (55) . In addition, the Osterix-Cre transgene exhibits some non-skeletal-cell targeting, including potential recombination in muscle (56) and causes defects in craniofacial development (57) ; however, we did not observe differential YAP/TAZ expression in skeletal muscle, and the allele dose-dependent response establishes YAP/TAZ specificity. These data demonstrate a critical combinatorial role for both YAP and TAZ in bone development and combinatorial function, evidenced by the rescue of neonatal lethality by a single intact allele of either gene.
A recent study found that YAP overexpression in developing chondrocytes, under control of the Col2a1 promoter, impairs bone development (31) . This finding appears to contradict our results; however, this study was not designed to isolate the role of YAP in the skeletal lineage and featured YAP overexpression in the cartilaginous anlage, as well as the osteoblast precursors. YAP has elsewhere been reported to negatively regulate chondrogenesis (58) , and changes in anlage formation may therefore alter bone development independent of defects in osteogenic cells. Further, the developmental phenotype appeared only in homozygously overexpressed transgenics, which points to the limitations of overexpression approaches for tightly regulated transcriptional regulators that may exhibit nonphysiologic transcriptional activity at high concentrations. Consistent with our observations that YAP and TAZ have compensatory roles, they did not observe statistically significant effects of Col2a1-conditional YAP deletion on skeletal development (31) . Similarly, Yang et al. (30) overexpressed TAZ in collagen Iexpressing cells and observed increased bone formation, consistent with the present data and the phenotype of the global homozygous TAZ knockout, which also presents bone development defects (20) . Synthesis of these studies indicates the importance of dual and combinatorial lossof-function approaches to interrogate YAP/TAZ compensatory function. 
YAP/TAZ-dependent gene expression
Bone cell-conditional YAP/TAZ deletion produced an allele dose-dependent phenotype characterized by defects in both osteogenesis and matrix composition, associated with reduced osteogenic and collagen-related gene expression. These transcriptional patterns were consistent in vitro and in vivo. YAP/TAZ deletion reduced osteogenic gene induction in isolated osteoprogenitors and reduced osteoblast numbers and mineral apposition rates in vivo, indicating that YAP/TAZ deletion impaired osteoblast differentiation and activation. Further, reduced collagen content and organization in vivo and impaired expression of Col1a1 and the endoplasmic reticulum-associated collagen chaperone, SerpinH1, suggest that YAP/TAZ regulate collagen production. These findings support a convergent, pro-osteogenic function for both YAP and TAZ (24-26, 29, 30) .
YAP and TAZ control gene expression through formation of transcriptional complexes with other transcription factors. These include TEAD1-4 and Runx2, among others (8) (9) (10) (11) (12) . Runx2 has been identified as a YAP/TAZ coeffector in osteogenesis in vitro (23) (24) (25) , but the role of TEAD in bone is unclear. To determine whether TEAD could be involved in YAP/TAZ regulation of osteogenesis-and collagen-related genes, we evaluated the effects of disrupting the YAP/TAZ-TEAD interaction, by using the small-molecule inhibitor VP, in vitro and in vivo. Quantification of YAP/TAZ-TEAD transcriptional activity and canonical downstream gene expression showed that VP treatment significantly inhibited YAP/TAZ-TEAD activity. Analysis of published chromatin immunoprecipitation sequencing data on the UCSC Genome Browser (University of California, Santa Cruz, CA, USA) (59) revealed that TEAD is capable of binding its canonical recognition sequence (39-ACATTCCA-59) in the promoter region of both Col1a1 and SerpinH1, suggesting the possibility of direct regulation. However, as YAP/TAZ are known to regulate gene expression through both promoter and enhancer binding, further research using chromatin immunoprecipitation combined with targeted mutagenesis is necessary, to isolate the binding domains and associated coeffectors. In contrast, VP treatment had no effect on Runx2 transcriptional reporter activity or direct Runx2 target genes (i.e., autoregulatory Runx2 or Osterix), either in vitro or in vivo. Despite this finding, expression of mature osteoblast markers was decreased by VP treatment, concomitant with Ocn promoter activity, suggesting that YAP/TAZ-TEAD may be involved in both osteogenic and collagen-related gene regulation. In vivo, VP treatment significantly reduced Col1a1 in the liver, but did not significantly alter gene expression in bone, most likely because of the small sample size and the 4-fold less efficient biodistribution of porphyrins to bone compared to liver (60, 61) . VP may also exhibit off-target effects (62), but both VP treatment and YAP/TAZ-conditional deletion produced consistent gene expression profiles.
These data demonstrate that YAP and TAZ have combinatorial roles in promoting skeletal development by regulating osteoblast activity, osteoclast-mediated remodeling, and matrix composition. 
